Today we announced $75 million in Series B-1 funding from GordonMD Global Investments. The proceeds will be used to advance our work to develop innovative therapies for #hepatitisB. Learn more: bit.ly/3EDYhrS #hepB #HBV

We've entered into an agreement with IRBM, INGM and OSR to acquire a series of novel capsid assembly modulators (CAMs) to treat #HepatitisB virus. This acquisition expands our pipeline and reiterates our commitment to #HBV. prn.to/3HgMd1Q

We're pleased to join fellow industry leaders at @HepDART 2021 discussing the science behind development of a functional cure for #HepatitisB virus. prn.to/3IBuMKj #HBV

Today we've announced that the first patient was dosed in combination treatment with Arbutus Biopharma in a #Clinical Trial for those with chronic #HepatitisB virus. bit.ly/3oRvP0G #HBV

We're attending @APASL2022 where we will be presenting new data on ATI-2173, our once-daily oral drug candidate for treating #HBV. Stay tuned for more information! bit.ly/35XjIYY #APASL2022

Today, we announced data results presented at @APASL2022 from SAVE-1, our Phase 1b and 2a study evaluating ATI-2173 for the treatment of #HepatitisB virus. prn.to/3iPQzlu #APASL2022

#DYK symptoms of #hepatitisB infection can include fatigue, poor appetite, stomach pain, and more? We are committed to finding a potential cure for chronic #HBV and other viral diseases. Learn more: bit.ly/3oy2qrP

Over 29 million individuals are infected with #HBV each year. Here at Antios, we have an ongoing commitment to developing innovative therapies to treat and potentially cure #HepatitisB virus, also known as HBV. #WorldHealthDay Learn more: bit.ly/35XjIYY

#DYK that over 290 million people worldwide are affected by #chronic #HepatitisB? Learn more about the opportunity we have to provide a functional cure for #HBV, an #InfectiousDisease. Visit our fact sheet to learn more: bit.ly/3LkBG7N

Join us at the 2nd Annual Chronic HBV and Drug Development Summit on April 25-27. Our very own Katherine Squires will be presenting on ASPIN for #chronic #HepatitisB infections. Learn more about our innovative therapies. bit.ly/35XjIYY

It's #WomensHealthMonth! We are committed to developing innovative therapies for #HBV, a global health crisis for women and children all over the world. Learn more: bit.ly/35XjIYY #NationalWomensHealthWeek

May is #HepatitisAwarenessMonth! With roughly 900,000 deaths per year, our mission at Antios is to develop innovative therapies to treat and cure #HBV Learn more: bit.ly/35XjIYY

Studies have shown that #AAPI make up the majority of #hepatitisB cases. This #AAPIHeritageMonth Antios would like to share free educational resources from the CDC for patients and caregivers. Learn more: bit.ly/3xiCe9P

Our mission at Antios is to develop innovative lifelong therapies to treat and cure #chronic hepatitis B. Read more on the search for innovative therapies based on the immune system in a recent nature article: bit.ly/36YEKY3

It's #HepatitisTestingDay! While #HBV can be an acute infection, it can also become a long-term, chronic infection that can lead to potentially life-threatening health conditions. Get tested today and visit our page to learn more: bit.ly/35XjIYY

#DYK symptoms of #HBV infection can include fatigue, poor appetite, stomach pain, nausea and jaundice? This #DigestiveDiseaseWeek we reiterate our commitment to treating and curing the 300,000 individuals chronically infected. Learn more: bit.ly/3oy2qrP

#Honored! Thank you to Georgia Life Sciences for recognizing us as a Deal of the Year. Learn more about Antios Therapeutics here: bit.ly/35XjIYY

Today, we announced our data have been accepted and will be presented at EASLnews #ILC2022 from ATI-2173, the company's leading therapeutic #HBV candidate, and our capsid assembly modulator program, ATI-1428 and ATI-1645. Learn more: bit.ly/3xxgCq1

June is #MensHealthMonth! Most healthy adults do not experience symptoms of #HBV when they are first infected. In many countries, #chronic hepatitis B rates are higher in males than in females. Learn more: bit.ly/35XjIYY

Today, we announced results at the EASLnews #ILC2022 on ATI-2173, ATI-1428 and ATI-1645. #Clinicaldata from the full Antios pipeline in #hepatitisB further validate the need to bridge to a cure for #HBV. Read more: prn.to/3NjVpo8